Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-03-30 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2022 annual report summary of a company (前沿生物药业（南京）股份有限公司). It contains detailed information about the company's business, products, research and development pipeline, industry analysis, financial performance indicators such as revenue and R&D expenses, and risk factors. It also mentions the audit report with an unqualified opinion by an accounting firm, which is typical in annual reports. The document is lengthy (15,000 characters) and contains substantive financial and operational data, not just an announcement or a brief summary. The content aligns with the characteristics of an Annual Report (10-K) filing, which covers company activity and full financial performance for the fiscal year. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-03-30 Chinese
前沿生物2022年年度报告
Annual Report Classification · 100% confidence The document is titled '2022 年年度报告' which translates to '2022 Annual Report'. It contains detailed company information, financial data, management discussion and analysis, risk factors, corporate governance, and audited financial statements. The presence of an audit report with an unqualified opinion is mentioned, and the document is extensive (15,000 characters, part of a 234-page report). It includes comprehensive financial metrics, quarterly data, and detailed operational and strategic discussions typical of a full annual report. There is no indication that this is merely an announcement or a summary; rather, it is the full official yearly report covering company activity and financial performance for the fiscal year 2022. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-03-30 Chinese
前沿生物2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2022 by the company 前沿生物药业（南京）股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification standards, and remediation status. The document is a detailed report on internal control evaluation rather than an announcement or a brief summary. It does not fit the definitions of Annual Report (10-K), Audit Report (AR), or other financial filings but is a standalone report focused on internal control evaluation. This type of document aligns best with the Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluation results. The document length is 4053 characters, which is sufficient to be a full report rather than a mere announcement. Therefore, the classification is AR with high confidence. FY 2022
2023-03-30 Chinese
国浩律师（南京）事务所关于前沿生物药业（南京）股份有限公司终止实施2021年限制性股票激励计划之法律意见书
Regulatory Filings
2023-03-30 Chinese
前沿生物关于第三届董事会第七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's third board meeting, including approval of the 2022 annual general manager work report, board work report, audit committee report, independent directors' report, financial statements, budget report, and other governance matters. It references the 2022 annual report and other reports but states these are disclosed separately on the stock exchange website. The document includes voting results and mentions that many resolutions require shareholder approval at the upcoming annual general meeting. The document is not the annual report itself but a board meeting resolution announcement. It also includes approval of capital raising authorizations and other corporate governance matters. Given the focus on board meeting resolutions and management reports, this fits best under Board/Management Information (MANG). The document length (6516 characters) and content confirm it is not a brief announcement or a full annual report but a detailed board meeting resolution announcement.
2023-03-30 Chinese
前沿生物关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2022 Annual General Meeting (AGM) of shareholders for a company, detailing the date, voting methods, agenda items, and procedural information for the meeting. It includes information about the meeting logistics, voting system, and proxy forms but does not contain any financial statements or results. The document is essentially an announcement and invitation to the AGM rather than the actual meeting materials or reports. Therefore, it fits the category of AGM Information (AGM-R). The document length is 4005 characters, which is consistent with a detailed AGM notice rather than a full report.
2023-03-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.